Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

A study has found that there is a dose-dependent relationship between increased risk for depression and cardiometabolic diseases.

Stroke burden and the contribution of several risk factors have increased from 1990 to 2021 on the global, regional, and national level.

Late morning eating time was associated with a lower risk for cardiovascular disease mortality among individuals with type 2 diabetes.

There is increased incidence of cardiovascular disease among patients who are immigrants that live in an area with low neighborhood-level income.

Lifetime occurrence of sleep talking was significantly associated with increased stroke risk, while occurrence of sleep talking in the past year did not have a significant association.

Dual antiplatelet therapy with clopidogrel and aspirin can benefit patients with mild ischemic stroke when initiated up to 72 hours after symptom onset.

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) warranting optimized management.

A risk model accurately identifies patients with severe asymptomatic carotid artery stenosis and predicts their risk for stroke and CVD.

A scientific statement regarding COVID-19-associated cardiac arrhythmias and autonomic dysfunction has been published by the AHA.

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.